Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: HIV Infections, Hepatitis C, Hemophilia
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C
Interventions: Sofosbuvir, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Montgomery, Alabama • Bakersfield, California + 55 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Chronic Hepatitis C
Interventions: CDI-31244, SOF/VEL; Drug
Lead sponsor: Cocrystal Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: Interferon Alfa-2b; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HEPATITIS C, Virus, Human Immunodeficiency
Interventions: Directly Observed Therapy, Wirelessly Observed Therapy; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Rialto, California + 12 more

Conditions: Hepatitis C Virus
Interventions: Ortho Tri-Cyclen®, BMS-650032; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cirrhosis
Interventions: Rotem; Other
Lead sponsor: Scott Allen; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more

Conditions: Hepatitis C Infection
Interventions: Boceprevir; Drug
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Riverside, California

Conditions: Hepatitis C, Pregnancy Complications
Interventions: Glecaprevir-pibrentasvir; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: HIV Infections, Hepatitis C
Interventions: Peer Education Intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 15 Years to 30 Years
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
Interventions: Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID); Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Colbert, Georgia

Conditions: Hepatitis C Virus
Interventions: Pegylated-Interferon-lambda, Ribavirin, Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 49
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hepatitis C
Interventions: Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir; Diagnostic Test · Other · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Long Island City, New York • New York, New York

Conditions: Hepatitis C, Chronic
Interventions: ISIS 14803, peginterferon alfa, ribavirin; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more

Conditions: Hepatitis C
Interventions: Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah

Search by objective public record fields.

Treatment of Hepatitis C in Hemophilic Patients With HIV

Phase 3 Study of Sofosbuvir and Ribavirin

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Antiviral Pharmacology and Adherence in Drug Users

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Drug Interaction Oral Contraceptive Pill (OCP)

Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure

Identifying the Gaps in the Diagnosis and Management of Hepatitis C

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Feasibility and Acceptability of HCV Treatment in Pregnancy

Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users

Voices From the Black Community: Hepatitis C Research Participation

Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies

Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

HCV Test and Treat Utilizing Simplified HCV Patient Education

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

Drug Interaction & Methadone & Buprenorphine